Teva Pharma (TEVA) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Reports First Quarter 2015 Results
April 30, 2015 7:01 AM EDTRevenues of $5.0 billion, in line with the first quarter of 2014. Organic revenue growth of 8% excluding the impact of foreign exchange fluctuations and the divestment of the U.S. OTC plants. Non-GAAP operating income of $1.5 billion, an increase of 11% compared to the first quarter of 2014. GAAP operating income of $749 million, down 23%. Non-GAAP net income of $1.2 billion, up 11%. GAAP net income of $446 million, a decrease of 40%. Non-GAAP diluted EPS of $1.36, an increase of 11%. GAAP diluted EPS of $0.52, a decrease of 40%.... More
